Solventum Corp

1. 1

   Election of Class II Directors

   ManagementBoard: FOR

   Election of four Class II director nominees to serve until the 2028 annual meeting.

2. 2

   Advisory Vote on Executive Compensation (Say on Pay

   ManagementBoard: FOR

   Non‑binding, advisory vote to approve the compensation of the company’s named executive officers as disclosed in the proxy statement.

   More detail

   This proposal requests a non‑binding, advisory approval of the company’s disclosed executive compensation for its named executive officers, giving shareholders an opportunity to express support or concern for pay practices. Management seeks this approval as required by Section 14A and to validate the design and outcomes of its pay program following the company’s separation from 3M and subsequent strategic actions, including divestitures, an acquisition, and a $1 billion share repurchase program. The compensation program emphasizes pay‑for‑performance: a large majority of CEO and NEO target pay is at risk (92% for CEO; 81% for other NEOs), with a mix of annual cash incentives tied to revenue, adjusted operating income and free cash flow and three‑year PSUs tied to cumulative revenue growth, adjusted EPS and relative TSR. The Talent Committee has adjusted plan design in response to shareholder feedback—adding relative TSR and strengthening ownership guidelines—while retaining discretion to make certain compensation adjustments for separation, transaction, or tariff impacts. Management frames these adjustments and the overall plan as necessary to attract and retain experienced MedTech leadership during a complex post‑spin transition and to align management incentives with long‑term shareholder value. The Board recommends a “FOR” vote, arguing the program’s metrics are rigorous, risk‑mitigating features (clawbacks, anti‑hedging, ownership guidelines) are in place, and the Committee conducts benchmarking and annual risk reviews. Because the vote is advisory, a negative outcome would prompt additional shareholder engagement and potential changes to compensation design; a favorable vote provides the Board and Talent Committee with validation to continue the current program. Evaluating the proposal requires weighing strong recent company performance and executive retention needs against the size and structure of pay packages and the discretion the Committee retains for certain adjustments and one‑time awards.

3. 3

   Ratification of PwC as Independent Registered Public Accounting Firm for 2026

   ManagementBoard: FOR

   Ratify the Audit Committee’s appointment of PricewaterhouseCoopers LLP as Solventum’s independent registered public accounting firm for fiscal year 2026.

Upcoming shareholder meetings at Solventum Corp’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Solventum Corp 2026 annual meeting?

Solventum Corp (SOLV) holds its 2026 annual shareholder meeting on Friday, May 15, 2026.

What is the record date for the Solventum Corp 2026 meeting?

The record date for the Solventum Corp 2026 meeting is Thursday, March 19, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Solventum Corp's 2026 meeting?

The board is presenting 4 director nominees at the Solventum Corp 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Solventum Corp 2026 meeting?

Shareholders will vote on 3 proposals at the Solventum Corp 2026 meeting, each tagged with who proposed it and the board's recommendation.